Drug Information

Drug (ID: DG00405) and It's Reported Resistant Information

• Name: Sanguinarine
• Synonyms: SANGUINARINE; 2447-54-3; Pseudochelerythrine; Sanguinarin; sangvinarin; Veadent; Sanguiritrin; SANGUINARIUM; Dimethylenedioxy benzphenanthridine; UNII-AV9VK043SS; C20H14NO4; EINECS 219-503-3; Benzophenanthridine alkaloid; BRN 3915507; AV9VK043SS; CHEBI:17183; NCGC00015959-03; CAS-2447-54-3; [1,3]Benzodioxolo[5,6-c]-1,3-dioxolo[4,5-i]phenanthridinium, 13-methyl-; DSSTox_RID_80748; DSSTox_CID_25204; DSSTox_GSID_45204; 13-Methyl[1,3]benzodioxolo[5,6-C][1,3]dioxolo[4,5-I]phenanthridin-13-Ium; Sangrovit; y-Chelerythrine; SR-01000075650
• Indication:
  In total 1 Indication(s)
  Dental disease [ICD-11: DA08]; Approved; [1]
• Drug Resistance Disease(s):
  Disease(s) with Resistance Information Discovered by Cell Line Test for This Drug (1 diseases)
  Epithelial ovarian cancer [ICD-11: 2B5D]; [1]
• Target: Sodium/potassium-transporting ATPase (SPT ATPase); AT1A1_HUMAN AT1A2_HUMAN AT1A3_HUMAN AT1B1_HUMAN AT1B2_HUMAN AT1B3_HUMAN; [1]
• Formula: C20H14NO4+
• IsoSMILES: C[N+]1=C2C(=C3C=CC4=C(C3=C1)OCO4)C=CC5=CC6=C(C=C52)OCO6
• InChI: 1S/C20H14NO4/c1-21-8-15-12(4-5-16-20(15)25-10-22-16)13-3-2-11-6-17-18(24-9-23-17)7-14(11)19(13)21/h2-8H,9-10H2,1H3/q+1
• InChIKey: INVGWHRKADIJHF-UHFFFAOYSA-N
• PubChem CID: 5154
• ChEBI ID: CHEBI:17183
• TTD Drug ID: D0T3NB
• VARIDT ID: DR00919

Type(s) of Resistant Mechanism of This Drug

  EADR: Epigenetic Alteration of DNA, RNA or Protein

  UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Epithelial ovarian cancer [ICD-11: 2B5D]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Key Molecule: Cancer susceptibility 2 (CASC2) [1]

• Molecule Alteration: Expression; Down-regulation
• Resistant Disease: Epithelial ovarian cancer [ICD-11: 2B5D.0]
• Experimental Note: Revealed Based on the Cell Line Data
• Cell Pathway Regulation: Cell apoptosis; Inhibition; hsa04210
• Cell Pathway Regulation: Cell proliferation; Activation; hsa05200
• Cell Pathway Regulation: Cell viability; Activation; hsa05200
• Cell Pathway Regulation: NF-kB signaling pathway; Activation; hsa04218
• Cell Pathway Regulation: PI3K/AKT/mTOR signaling pathway; Activation; hsa04151
• In Vitro Model: SkOV3 cells; Ovary; Homo sapiens (Human); CVCL_0532
• In Vitro Model: A2780 cells; Ovary; Homo sapiens (Human); CVCL_0134
• In Vitro Model: OVCAR3 cells; Ovary; Homo sapiens (Human); CVCL_0465
• In Vitro Model: HO8910 cells; Ovary; Homo sapiens (Human); CVCL_6868
• In Vitro Model: CAOV3 cells; Ovary; Homo sapiens (Human); CVCL_0201
• Experiment for Molecule Alteration: qRT-PCR
• Experiment for Drug Resistance: MTT assay; Transwell assay; Flow cytometry assay
• Mechanism Description: Sanguinarine exhibits antitumor effects in epithelial ovarian cancer cells possible via regulating CASC2-EIF4A3 axis and/or inhibiting NF-kB signaling or PI3k/AkT/mTOR pathway and IF4A3 was identified as a CASC2 binding protein, and knockdown of EIF4A3 further reversed the effects of sanguinarine plus CASC2 silencing.

Unusual Activation of Pro-survival Pathway (UAPP)

Key Molecule: Eukaryotic initiation factor 4A-III (EIF4A3) [1]

• Molecule Alteration: Expression; Up-regulation
• Resistant Disease: Epithelial ovarian cancer [ICD-11: 2B5D.0]
• Experimental Note: Revealed Based on the Cell Line Data
• Cell Pathway Regulation: Cell apoptosis; Inhibition; hsa04210
• Cell Pathway Regulation: Cell invasion; Activation; hsa05200
• Cell Pathway Regulation: Cell migration; Activation; hsa04670
• Cell Pathway Regulation: Cell viability; Activation; hsa05200
• Cell Pathway Regulation: NF-kB signaling pathway; Activation; hsa04218
• Cell Pathway Regulation: PI3K/AKT/mTOR signaling pathway; Activation; hsa04151
• In Vitro Model: SkOV3 cells; Ovary; Homo sapiens (Human); CVCL_0532
• In Vitro Model: A2780 cells; Ovary; Homo sapiens (Human); CVCL_0134
• In Vitro Model: OVCAR3 cells; Ovary; Homo sapiens (Human); CVCL_0465
• In Vitro Model: HO8910 cells; Ovary; Homo sapiens (Human); CVCL_6868
• In Vitro Model: CAOV3 cells; Ovary; Homo sapiens (Human); CVCL_0201
• Experiment for Molecule Alteration: Western blot analysis
• Experiment for Drug Resistance: MTT assay; Transwell assay; Flow cytometry assay
• Mechanism Description: Sanguinarine exhibits antitumor effects in epithelial ovarian cancer cells possible via regulating CASC2-EIF4A3 axis and/or inhibiting NF-kB signaling or PI3k/AkT/mTOR pathway and IF4A3 was identified as a CASC2 binding protein, and knockdown of EIF4A3 further reversed the effects of sanguinarine plus CASC2 silencing.

References

• Ref 1: Sanguinarine inhibits epithelial ovarian cancer development via regulating long non-coding RNA CASC2-EIF4A3 axis and/or inhibiting NF-kB signaling or PI3K/AKT/mTOR pathway. Biomed Pharmacother. 2018 Jun;102:302-308. doi: 10.1016/j.biopha.2018.03.071. Epub 2018 Mar 22.